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LINE1 and a-satellite repeats (Bryzgunova, 2011). Results: TEM
with immunogold labeling demonstrate presence of exosomes
in 30–100 nm membrane-wrapped particles isolated from both
plasma and CSB eluates. TEM, NanoOrange and 28S rRNA
RT-qPCR data demonstrate that CSB exosomes constitutes 2/3 of
total blood exosomes. Exosomes ranged 50–70 nm prevail in blood
of BCP, whereas 30–50 nm exosomes in blood of HW. Exosomal
DNA is less than 0.3% of cell-free blood DNA. RNA integrity and
specific quantity checked by Bioanalyzer (Agilent Technologies,
USA) do not differ in cell-free and CSB exosomes. Preliminary
data demonstrate overpresentation of cancer-specific miRNA
(miR-103, miR-191, miR-195) in exosomes bound with erythro-
cyte’s as compared with exosomes bound with leukocytes or
circulating in plasma.
Conclusion: Exosomal DNA obviously do not have any diagnos-
tic value in contrast to RNA. CSB exosomes represent valuable
source of material for small-invasive cancer diagnostics.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.106
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Background: It was shown that circulating DNA could be used
as a valuable source of material for cancer diagnostics
(Fleischhacker, 2007), but unknown and unpredictable factors
frequently dramatically decrease concentration of tumor-
specific genetic biomarkers by influencing on generation and cir-
culation in bloodstream of extracellular DNA. Sequencing of total
circulating DNA could either provide valuable information regard-
ing such factors or determine novel targets (DNA markers) for
cancer diagnostics.
Materials and Methods: We used a Sanger’s technology (ABI
PRIZM 3110 sequenator) and BLAST analysis of circulating DNA
from plasma and cell-surface-bound fraction of healthy individu-
als and patients with breast cancer. DNA was isolated by guani-
dine thiocyanate/glass milk method (Tamkovich, 2004) followed
by Sau3A and EcoRI hydrolysis. Fragmented DNAwas ligated into
the pBlueScript II KS(-) vector. Competent XL-Blue (E. coli) cells
were transformed with the vector by electroporation and after
recovery the cells were plated on LB+Amp agar plates. The inserts
length estimate by PCR-analysis.
Results: The majority of investigated circulating DNA frag-
ments were about 100–800 bp. Sequence analysis revealed that
number of circulating DNA fragments does not depend from the
size of paternal chromosome both in normal and pathological
state, but fragments from chromosome six were found in the
female bloodstream more frequently. It was found, that in cancer
patients blood were observed frequency of occurrence of pseudo
genes and CpG islands below then in healthy female blood. BLAST
analysis demonstrates that 10% of coding DNA fragments circu-
lating in blood of the breast cancer patients is associated with
development of this pathology.
Conclusion: Sequencing of circulating DNA demonstrates a
variable concentration of different DNA sequences in comparison
with genomic DNA. Further characterization of circulating DNA
may be beneficial in diagnosis and prognosis and may also con-
tribute to determining the source and function of circulating
DNA.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.107
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Prostate cancer is presented as the most commonly diag-
nosed cancer in men. According to statistical reports, every
6th man have the prostate cancer and out of them every 34th
man will have the castrate-resistant form of disease. The exist-
ing clinical and prognostic factors can explain cancer outcome
in small part of patients. The prediction of individual prostate
cancer prognosis and anticancer therapy effect are the main
goals of the advanced personalized therapy. The modern genetic
technologies development (GWAS, genome sequencing) will
allow to find the effective prognostic markers of prostate
cancer.
During the GWAS performance it was found loci associated
with the prostate cancer development. The analysis of on-line
base ‘‘A Catalog of Published Genome-Wide Association Studies”
(www.genome.gov), containing the full information of genome
associative investigations as well as 30 studies of prostate cancer,
revealed the associations of 159 SNPs in different ethnic groups of
patients (Caucasian, Asian and Negroid). 86 SNPs among them
located in 77 genes, 65 SNPs – had the intergenic localization.
The GWAS performance in prostate cancer Caucasian patients
have found the associations of 76 SNPs in 72 genes and 65 SNPs
in intergenic regions. SNPs in genes were located in 81.4% of cases
in introns, in 5.3% – in other locations as well as missense
changes (near 50-UTR, ncRNA). It was obtained 30 markers related
to disease of different ethnic groups of patients in GWAS. 17 SNPs
among them (rs10187424, rs6545977, rs7584330, rs10936632,
rs651164, rs12155172, rs1512268, rs4242384, rs3123078,
rs11199874, rs7127900, rs7130881, rs10875943, rs4775302,
rs5759167, rs1327301, rs5919432) had the intergenic localization,
12 SNPs (rs1465618, rs12621278, rs17181170, rs6763931,
rs17021918, rs12500426, rs7679673, rs2121875, rs2242652,
rs6465657, rs7501939, rs1859962) were located in introns and
1 SNP (rs130067) – in exon.
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